Antibiotics improve survival and alter the inflammatory profile in a murine model of sepsis from Pseudomonas aeruginosa pneumonia

Shock

Volumn 19, Issue 5, 2003, Pages 408-414

  Coopersmith, Craig M ^a   Amiot II, Daniel M ^a   Stromberg, Paul E ^a   Dunne, W Michael ^a   Davis, Christopher G ^a   Osborne, Dale F ^a   Husain, Kareem D ^a   Turnbull, Isaiah R ^a   Karl, Irene E ^a   Hotchkiss, Richard S ^a   Buchman, Timothy G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Gentamicin; Imipenem; Infection; Interleukin 10; Interleukin 12; Interleukin 6; Tumor necrosis factor

Indexed keywords

ANTIBIOTIC AGENT; CYTOKINE; GENTAMICIN; IMIPENEM; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; INFLAMMATION; MORTALITY; MOUSE; NONHUMAN; PNEUMONIA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; SEPSIS; SURVIVAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CYTOKINES; DISEASE MODELS, ANIMAL; GENTAMICINS; IMIPENEM; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED STRAINS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEPSIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 4644339849     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000054370.24363.ee     Document Type: Article

References (36)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310, 2001.
2. Murphy SL: Deaths: final data for 1998. NatlVital Stat Rep 48:1-105, 2000.
3. Sawa T, Corry DB, Cropper MA, Ohara M, Kurahashi K, Wiener-Kronish JP: IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J Immunol 159:2858-2860, 1997.
4. Bodey GP, Bolivar R, Fainstein V: Jadeja: infections caused by Pseudomonas aeruginosa. Rev Infect Dis 5:279-313, 1983.
5. Rouby JJ: Nosocomial infection in the critically ill: the lung as a target organ. Anesthesiology 84:757-759, 1996.
6. Coopersmith CM, Stromberg PE, Dunne WM, Davis CG, Amiot DM, Buchman TG, Karl IE, Hotchkiss RS: Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. J Am Med Assoc 287:1716-1721, 2002.
7. Hotchkiss RS, Dunne WM, Swanson PE, Davis CG, Tinsley KW, Chang KC, Buchman TG, Karl IE: Role of apoptosis in Pseudomonas aeruginosa pneumonia. Science 294:1783, 2001.
8. Grassme H, Kirschnek S, Riethmueller J, Riehle A, von Kurthy G, Lang F, Weller M, Gulbins E: CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 290:527-530, 2000.
9. Starke JR, Edwards MS, Langsten C, Baker CJ: A mouse model of chronic pulmonary infection with Pseudomonas aeruginosa and Pseudomonas cepacia. Pediatr Res 22:698-702, 1987.
10. Yu P, Martin CM: Increased gut permeability and bacterial translocation in Pseudomonas pneumonia-induced sepsis. Crit Care Med 28:2573-2577, 2000.
11. Schultz MJ, Rijneveld AW, Florquin S, Edwards CK, Dinarello CA, van der Poll T: Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol 282:L285-L290, 2002.
12. Skerrett SJ, Martin TR, Chi EY, Peschon JJ, Mohler KM, Wilson CB: Role of the type 1 TNF receptor in lung inflammation after inhalation of endotoxin or Pseudomonas aeruginosa. Am J Physiol 276:L715-L727, 1999.
13. Kaneko Y, Yanagihara K, Kuroki M, Ohi H, Kakeya H, Miyazaki Y, Higashiyama Y, Hirakata Y, Tomono K, Kadota JI, Kohno S: Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia. Chemotherapy 47:421-429, 2001.
14. Newcomb D, Bolgos G, Green L, Remick DG: Antibiotic treatment influences outcome in murine sepsis: mediators of increased morbidity. Shock 10:110-117, 1998.
15. Deitch EA: Animal models of sepsis and shock: a review and lessons learned. Shock 9:1-11, 1998.
16. Remick DG, Newcomb DE, Bolgos GL, Call DR: Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13:110-116, 2000.
17. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Heiterbrand JD, Ely EW, Fisher CJ: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001.
18. Abraham E, Marshall JC: Sepsis- and mediator-directed therapy: rethinking the target populations. Mediator-directed therapy in sepsis: rethinking the target populations. Mol Med Today 5:56-58, 1999.
19. Munford RS, Hall CL, Grimm L: Detection of free endotoxin in cerebrospinal fluid by the limulus lysate test. Infect Immun 45:531-533, 1984.
20. Shenep JL, Mogan KA: Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis 150:380-388, 1984.
21. Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA: Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704-1710, 1989.
22. Waage A, Brandtzaeg P, Halstensen, Kierulf P, Espevik T: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 169:333-338, 1989.
23. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA: Six at six: Interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463-467, 2002.
24. Negussie Y, Remick DG, DeForge LE, Kunkel SL, Eynon A, Griffin GE: Detection of plasma tumor necrosis factor, and interleukins 6 and 8 during the Jarisch-Herxheimer reaction of relapsing fever. J Exp Med 175:1207-1212, 1992.
25. Tateda K, Matsumoto T, Miyazaki S, Yamaguchi K: Efficacy of β-lactam antibiotics combined with gentamicin against penicillin-resistant pneumococcal pneumonia in CBA/J mice. J Antimicrob Chemother 43:367-371, 1999.
26. Bohnen JM, Solomkin JS, Dellinger EP, Bjornson HS, Page CP: Guidelines for clinical care: Anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg 127:83-89, 1992.
27. Sawa T, Kurahashi K, Ohara M, Cropper MA, Doshi V, Larrick JW, Wiener-Kronish JP: Evaluation of antimicrobial and lipopolysaccharide- neutralizing effects of a synthetic CAP18 fragment against Pseudomonas aeruginosa in a mouse model. Antimicrob Agents Chemother 42:3269-3275, 1998.
28. Pennington JE, Stone RM: Comparison of antibiotic regimens for treatment of experimental pneumonia due to Pseudomonas. J Infect Dis 140:881-889, 1979.
29. Schiff JB, Small GJ, Pennington JE: Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother 26:1-4, 1984.
30. Gordin FM, Rusnak MG, Sande MA: Evaluation of combination chemotherapy in a lightly anesthetized animal model of Pseudomonas pneumonia. Antimicrob Agents Chemother 31:398-403, 1987.
31. Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D: Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun 67:6603-6610, 1999.
32. Baker CC, Chaudry IH, Gaines HO, Baue AE: Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94:331-335, 1983.
33. Chaudry IH, Wichterman KA, Baue AE: Effect of sepsis on tissue adenine nucleotide levels. Surgery 85:205-211, 1979.
34. Coopersmith CM, Chang KC, Swanson PE, Tinsley KW, Stromberg PE, Buchman TG, Karl IE, Hotchkiss RS: Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice. Crit Care Med 30:195-201, 2002.
35. Goebel A, Kavanagh E, Lyons A, Saporoschetz IB, Soberg C, Lederer JA, Mannick JA, Rodrick ML: Injury induces deficient interleukin-12 production, but interleukin-12 therapy after injury restores resistance to infection. Ann Surg 231:253-261, 2000.
36. O'Sullivan ST, Lederer JA, Horgan AF, Chin DH, Mannick JA, Rodrick ML: Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg 222:482-490, 1995.